According to the latest financial report of Halozyme Therapeutics, the latest earnings per share (TTM) for the company is 1.05. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Halozyme Therapeutics's free cash flow? The latest report shows it as 113.86M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Halozyme Therapeutics shows that the company's current ratio is 10.36, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Halozyme Therapeutics, the quick ratio is 8.75, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Halozyme Therapeutics? The latest ROE figure is 36.92%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Halozyme Therapeutics, the total asset return on investment (ROA) is 6.70%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Halozyme Therapeutics's latest financial report to see how their gross margin is doing - currently at 82.96%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Halozyme Therapeutics, the net profit margin is 47.23%, which is a good sign for its profitability.